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EVIDENCE FOR THE ASSOCIATION OF THE 4Q32-34 LOCUS
AND PANCREATIC CANCER IN EUROPEAN FPC FAMILIES
J Earl 1, L Yan 1, C McFaul 1, R Kress 2, J Leslie 1, H Rieder 2,
M Sina-Frey 2, S Hahn 3, D Bartsch 2, W Greenhalf 1, J Neoptolemos 1
1 The University of Liverpool, Liverpool, United Kingdom,
2 Philipps-University, Marburg, Germany, 3 University of Bochum,
Bochum, Germany
Introduction: Familial Pancreatic Cancer (FPC) is a rare autosomal
dominant disease, the causative gene of which is unknown. However, the
locus 4q32-34 has been implicated in one large US Kindred. This locus
contains genes involved in DNA repair (HMGB2), apoptosis (PPID) and cell
cycle control. The European registry of Hereditary Pancreatitis and Familial
Pancreatic Cancer (EUROPAC) in collaboration with the FaPaCa group in
Germany has recruited over 150 families with pancreatic cancer. 
Aim: Is the 4q32-34 locus associated with FPC families.
Methods: The 4q32-34 locus has been haplotyped in affected and unaffected 
individuals in 41 EUROPAC and FaPaCa families that fulﬁ  l our criteria for 
FPC. The locus was haplotyped with 9 mapping pairs covering an area of 
15cM. Alleles are deﬁ  ned on the basis of size and haplotypes assigned to
each individual. High Mobility Group Box 2 (HMGB2) and cyclophillin D
(PPID) genes have been sequenced in 10 different FPC families.
Results:We have excluded linkage to the 4q32-34 locus in 7 families. Of the
remaining 34 linkage cannot be excluded due to either the lack of biological
samples or that the disease status of individuals cannot be conﬁ  rmed as they
are considered too young to develop the disease or be classed as unaffected.
A total of 55 haplotypes have been identiﬁ  ed as possibly being linked to the
disease and a further 75 haplotypes have been ruled out. Potential disease
causing mutations or nucleotide polymorhisms have not been identiﬁ  ed by
DNA sequencing of HMGB2 and PPID genes in FPC patients so far.
Conclusions: L inkage to the 4q32-34 locus  has  been excluded  in 7/41
families analysed, LOD score analysis will enable us to determine the
likelihood of this locus being linked in all of our families. EUROPAC and 
FaPaCa continue to recruit new families in order to continue the study of this
locus and to identify other potential loci.
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THE CALCIUM BINDING PROTEIN S100A6 (CALCYCLIN) AS A
PROGNOSTIC INDICATOR IN PANCREATIC CANCER
D Vimalachandran 1, R Watson 1, A Shekouh 1, C Thompson 1,
F Campbell 2, W Prime 2, T Crngorac-Jurcevic 4, N Lemoine 4,
J Neoptolemos 1, E Costello 1
1 Department of Surgery, University of Liverpool, Liverpool, United 
Kingdom, 2 Department of Pathology, Royal Liverpool University
Hospital, Liverpool, United Kingdom, 3 Department of Human
Anatomy and Cell Biology, Liverpool, United Kingdom, 4 Cancer 
Research UK Molecular Oncology Unit, London, United Kingdom
INTRODUCTION: Pancreatic cancer is a devastating disease, responsible for
approximately 40,000 deaths in Europe each year. Using both RNA expression
analyses and proteomics based studies we have previously demonstrated increased
expression of the calcium binding protein S100A6 in pancreatic cancer. The
aim of this study was to determine the signiﬁ  cance of S100A6 expression as a
prognostic indicator in comparison to other clinicopathologic parameters.
METHODS:  Immunohistochemical analysis was performed on a tissue micro-
array o f s ixty pancreatic cancer tissue specimens. The  intensity o f staining
[negative (undetectable), weak, intermediate, strong] was scored along with
the proportion of cells staining. For the purposes of analysis, immunoreactivity
(expression) was categorised into two groups; undetectable or weak (“low
expression”) and  intermediate or strong (“high expression”). Univariate and
multivariate survival analysis was then performed using S100A6 expression and
other commonly used clinicopathologic parameters.
RESULTS: High S100A6 expression was observed in 40(80%) of 60 patients.
Kaplan-Meier analysis revealed a signiﬁ   cantly decreased survival time in
high S100A6 expressing cases (p=0.02) when compared with low expression.
Nodal metastases (p=0.05) and resection margin involvement (p=0.04) were
also signiﬁ  cantly associated w ith survival. Multivariate analysis with a Cox
proportional hazards model using S100 expression, nodal status and resection
margin status revealed S100A6 expression to be a signiﬁ  cant  independent
prognostic indicator (p=0.008).
CONCLUSIONS: Our ﬁ  ndings suggest S100A6 may be at least as powerful
a determinant of survival as existing prognostic indicators. The exact role that
S100A6 plays in pancreatic adenocarcinoma is at present unknown. The ﬁ  ndings
of this study, and the implication that S100A6 may play a signiﬁ  cant role in
pancreatic tumour progression, clearly merit further investigation.
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IN DESIGNING CLINICAL TRIALS CAN WE PREDICT 
SURVIVAL OUTCOME FOR OUR PATIENTS WITH RENAL CELL
CARCINOMA FOLLOWING NEPHRECTOMY?
GWA Lamb 1, DC McMillan 2, EJ Bromwich 1, PA Vasey 3,
M Aitchison 1
1 Department Of Urology, Gartnavel General Hopspital, Glasgow, 
United Kingdom, 2 Department Of Surgery, Glasgow Royal Inﬁ  rmary, 
Glasgow, United Kingdom, 3 Beatson Oncology Centre, Western 
Inﬁ  rmary, Glasgow, United Kingdom
Introduction: Prognostic algorithm models are of particular value in the
design of clinical trials.  The UCLA Integrated Staging System (UISS) and 
The Mayo Clinic Ssign score, are two predictive models, based on American
data [J Clin. Oncol 2002; 20(23): 4559-4566 / l J Urol 2002; 168(6): 2395- l
2400] for stratifying renal cell carcinoma (RCC) patients into prognostic
groups following nephrectomy.   To date there is no predictive algorithm
designed on a UK population base.  We evaluated each model to determine if 
they are applicable to a UK population.
Patients and Methods: 145 patients (95 male, 50 female) with clear cell
tumours and for whom all the data required to calculate a predictive score
for both models was available, were identiﬁ  ed retrospectively from the 502
patients in our renal cancer database. 29 were node positive or had had 
cytoreductive nephrectomy.  The remaining 116 had had potentially curative
surgery.  Cox regression analysis was used to deﬁ  ne hazard ratios (HR) and 
survival.
Results:  Twenty n ine  disease speciﬁ  c  deaths were recorded  (13  from
potentially curative group, 16 from advanced group).  Median follow up
was 39 months.  Both the Ssign score (HR 1.36, 95%CI 1.12-1.64, p=0.002)
and UISS (HR 1.87, 95%CI 1.44-2.42, p<0.001) were highly signiﬁ  cant at
predicting survival outcome following nephrectomy.  Only the UISS score
remained signiﬁ  cant (HR 3.84, 95%CI 1.39-10.58, p<0.009) when patients
with metastatic disease were excluded from analysis.
Conclusion: These models predict outcome following nephrectomy when
applied to a UK population.  The Ssign score was a good predictor of overall
mortality however relied on patients with metastases at the time of surgery
to maintain signiﬁ   cance.  Only the UISS system signiﬁ  cantly  predicted 
outcome  in  both  localised and metastatic  disease and  is the model we
recommend for use in the U.K. when designing clinical trials.
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A COMBINED ONCOLOGY/ SURGICAL RENAL CANCER 
CLINIC PROVIDES A COMPREHENSIVE CANCER SERVICE
AND INCREASES RECRUITMENT FOR CLINICAL TRIALS
GWA Lamb 1, PA Vasey 2, EJ Bromwich 1, M Aitchison 1
1 Department Of Urology, Gartnavel General Hospital, Glasgow, 
United Kingdom, 2 Beatson Oncology Centre, Western Inﬁ  rmary, 
Glasgow, United Kingdom
Introduction: Since 1999 our regional referral centre has provided  a
combined oncology/ surgical clinic for patients diagnosed with metastatic
renal cancer (RCC). RCC is a rare tumour accounting for 2% of all adult
malignancies.  Survival beneﬁ  t has been demonstrated combining treatments
of immunotherapy, cytoreductive nephrectomy, excision of local recurrence
and solitary metastasectomy.  The provision of a combined service allows for
rapid assessment and constructive management planning using these various
treatment modalities and higher levels of recruitment for clinical trials.
Materials and Methods: The clinic is lead by a consultant oncologist and a
consultant urological surgeon.  A cardiothoracic and a general surgeon are
available for consultation at short notice.  A dedicated clinical research nurse
based in the clinical research unit running several clinical trials in renal
cancer simultaneously supports the clinic.
Results: Between1999 and 2003 386 new patients have been seen at the
combined clinic.  26 patients underwent cytoreductive nephrectomy, 24
metastasectomy and 8 excision of local recurrence.  A database of 526
patients with RCC has  been established.  Trials  include; EORTC U70
(Adjuvant RCC)-21 patients entered, UK total entry 126 (23 centres).  U79
MRC RE04 (Advanced RCC)-29 patients entered, UK total entry 311 (28
centres).  U80 ICRF (Advanced RCC)- 4 patients entered.
Discussion: On their initial visit patients are assessed for trial eligibility
and surgery by both consultants within the primary team.  Follow up is at
the same clinic allowing surgical and oncological complications to be dealt
with by the appropriate specialist.  More patients attending our institution
are proceeding to surgical intervention in the course of their treatment.  Our
single institution accounts for 16.7% and 9.3% total UK recruitment of the
U70 adjuvant and U79 trials respectively.  A combined oncology/ surgical
renal cancer clinic provides patients with a comprehensive cancer service on
a single visit which beneﬁ  ts from increased recruitment for clinical trials.
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A RANDOMISED PHASE II STUDY OF INTERFERON-Α ALONE 
OR IN COMBINATION WITH THALIDOMIDE IN METASTATIC
RENAL CELL CARCINOMA
S.R Muthuramalingam 1, S Madhusudan 1, P.A Vasey 2, P Patel 3,
K Christodolus 1, A Protheroe 1, A.L Harris 1
1 United Kingdom, CRUK Medical Oncology Unit, Churchill Hospital,
Oxford, OX3 7LJ, 2 United Kingdom, CRC Department of Medical 
Oncology, Beatson Oncology Centre, Western Inﬁ  rmary, Glasgow,
G11 6NT, 3 United Kingdom, Institute of Cancer Studies, St.James’s
University Hospital, Leeds LS9 7TF
Interferon-α (INF) is the standard treatment for patients with metastatic renal α
cell carcinoma. Renal cell carcinomas are highly vascular with elevated levels
of TNF-α, an angiogenic cytokine. Thalidomide (T) is anti-angiogenic and 
increases the degradation of the mRNA of TNF-α. We report results of an 
interim analysis of our randomised study to investigate the role of thalidomide
in combination with the INF-α.
Metastatic renal cell carcinoma patients were randomised to receive either 
INF-α alone in the dose of 4.5 MIU SC for the ﬁ  rst two doses followed by 9  α
MIU SC three times a week or in combination with thalidomide 200mg/day 
orally. Randomisation is based on three prognostic groups, good, moderate
or poor. 
Patients characteristics were as follows: 34 patients, 22 male, 12 female,
median age 57 years (range 44-76), ECOG PS= 0 to 1 in 30 and PS=2 in 4, 9
in good prognostic group, 19 in moderate and 6 in poor prognostic groups.16
received INF-α alone (INF) and 18 received INF-α+Thalidomide (INF+T). 20
completed ≥ 12 weeks of treatment. In the 20 evaluable patients for response
the response rates were as follows: in INF arm (12): CR 1, SD 9 and PD 2; in 
INF+T arm (8): PR 1, SD 2 and PD 5. In 14 who received < 12 weeks treatment,
1 withdrew from study, 13  (5 in INF arm and 8 in INF+T arm) withdrew due to
toxicity. GIII toxicities were as follow: anaemia (0 vs.4: INF vs. INF+T), skin 
rash (0 vs. 2: INF vs. INF+T), dizziness (0 vs.2: INF vs. INF+T), fatigue (5
vs. 2: INF vs. INF+T), anorexia (1 in both arms), thrombocytopenia (1 vs. 0:
INF vs. INF+T), neutropenia (2 in both arms). GII peripheral neuropathy was
observed more in INF+T arm (0 vs. 3: INF vs. INF+T).
INF-α and thalidomide combination is reasonably well tolerated but with  α
increased incidence of anaemia, skin rash and peripheral neuropathy in the
combination arm.
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IDENTIFICATION OF MARKERS/ANTIGENS IN RENAL CELL
CARCINOMA
RA Craven 1, AJ Stanley 1, JS Dods 2, RD Unwin 1, S Hanrahan 2,
N Totty 2, S Lloyd 3, P Harnden 4, PJ Selby 1, RE Banks 1
1 United Kingdom, Cancer Research UK CLinical Centre, St james’s
University Hospital, Leeds, 2 United Kingdom, Cancer Research UK 
Protein Sequencing Laboratory, Lincolns Inn Fields, London, 3 United 
Kingdom, Department of Urology, St James’s University Hospital,
Leeds, 4 United Kingdom, Department of Pathology, St James’s
University Hospital, Leeds
Renal cell carcinoma (RCC) accounts for 2-3% of adult malignancies
with a large number of patients having locally advanced or metastatic
disease at the time of diagnosis. RCC remains highly refractory to current
chemotherapy and radiotherapy regimens, although promising responses
to immunotherapy have been reported in a signiﬁ  cant subset of patients.
Currently there are no reliable markers/antigens for monitoring/detection
of disease or for use as therapeutic targets. The aim of this study was to
identify such molecules using proteomic-based approaches.
Two dimensional gel electrophoresis in conjunction with mass
spectrometry has been used to examine the protein proﬁ  les of primary
cultures of epithelial cells grown from matched normal kidney cortex and
RCC samples. Comparative analysis highlighted 43 proteins upregulated
in at least 3 out of 5 RCC primary cell lines and 29 proteins down regulated
in at least 4 out of 5 RCC primary cell lines. The identities of 63 of these
proteins have been determined to date. Changes in the expression of a
number of the proteins identiﬁ  ed here have been previously described in
RCC, including Hsp27 and several glycolytic and mitochondrial enzymes.
In addition several of the proteins found to be differentially expressed in this
study are novel ﬁ  ndings. Several of these proteins are currently undergoing
downstream validation using a panel of primary and established cell lines
as well as normal and malignant renal tissue samples.
The results of this study will be presented and compared to proteins
identiﬁ  ed by a similar proteomic analysis of whole tissue lysates.
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PREDICTIVE VALUE OF P53 IN DETECTION OF RECURRENCE
AND PROGRESSION IN T1 G2-G3 TRANSITIONAL BLADDER 
CARCINOMA
MH amdi 1, AG Smith 2, A O’Grady 2, DP Hickey 1, EW Kay 1
1 United Kingdom, UROLOGY DEPARTEMENT BEAUMONT
HOSPITAL, DUBLIN, 2 Ireland, PATHOLOGY DEPARTEMENT,
BEAUMONT HOSPITAL AND THE ROYAL COLLEGE OF
SURGEONS IN IRELAND, DUBLIN
Introduction: Much controversy surrounds the management of T1 G2-
G3 transitional cell carcinoma (TCC) of the bladder. Radical surgery
is over treatment in at least 50% of cases. One of the most common
genetic changes associated with all types of cancer in humans is an
alteration of the p53 gene. Our study helps to determine whether p53
expression in T1 G2-G3 bladder cancer can be correlated with disease
recurrence or progression.
Patients and Methods: From January 1991 until March 2003, 83
patients were diagnosed with T1 G2-G3 TCC of the bladder. Six
(7%) patients were excluded due to insufﬁ  cient pathological material.
Immunohistochemical staining for p53 was carried out on parafﬁ  n-
embedded tumour specimens using the p53-DO7 murine monoclonal
antibody. Immuno-reactivity was categorized as either positive
(reactivity in 10% or more tumour cells) or negative.
Results: Median follow up was 3.5 years (range 6mts to 12yrs). Fifty-
four (70.1%) tumours were p53 positive while 23 (29.9%) tumours were
p53 negative.  Thirty-seven (68.52%) of the positive cases recurred 
while 15 (65.2%) of the negative cases recurred (p 0.56). Seventeen
(31.48%) of the p53 positive cases progressed while 7 (30.34%) of the
negative group progressed (p 0.66). 
Conclusions: Our results indicate that the percentage of p53
immunomarked cells cannot currently be used to predict recurrence and 
progression in T1 G2-G3 transitional bladder cancer
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CODING OF SUPERFICIAL BLADDER CANCER – AUDIT 
COMPARING A DISTRICT GENERAL HOSPITAL (DGH) AND ITS
REGIONAL CANCER INTELLIGENCE UNIT (RCIU)
D Hayne, BK Somani, C Mellors, AM Light, H Ojha,
DR Thomas, MC Foster 
1 Sandwell & West Birmingham Hospitals NHS Trust, Birmingham,
United Kingdom, 2 Good Hope Hospital, Birmingham, United 
Kingdom, 3 West Midlands Cancer Intelligence Unit, Birmingham,
United Kingdom
Coding of superﬁ  cial bladder cancer has been controversial. Accuracy of
regional cancer registry data has been questioned. Coding of non-invasive
TCC bladder from our district general hospital (DGH) was compared with
the regional cancer intelligence unit (RCIU).
All cases of superﬁ  cial non-invasive bladder cancer (pTa and CIS) over a 5
year period 01/01/1996 – 31/12/2001 were identiﬁ  ed from DGH database
and matched with RCUI registry data using NHS no, hospital no, DOB and
patient details. Both databases were further interrogated about individual
cases where differences were identiﬁ  ed between the data sets. The assigned
histopathological codes were also compared. 
Of 402 identiﬁ   ed cases 389 (97%) were successfully matched with the
regional registry. Of the 13 (3%) missing cases 10 were not registered and 3
were registered but only with another primary tumour.
14 (3.5%) were coded as a different urological cancer site (renal pelvis/
ureter not bladder) due to: no deﬁ  nite cancer being identiﬁ  ed (DGH coding
error –3 patients), no pathology report being sent to /received by RCUI
(communication error –2 patients) or the cancer site being miscoded due to
a known problem with multiple site coding (RCIU coding policy variation
-10 patients).
50 (12%) cases showed discrepancy in the assigned histological code. The
majority had been miscoded as non-invasive by DGH probably due to use
of an older and potentially misleading coding system. In a few cases no
pathology report had been sent/received or the case progressed to invasive
disease. No cases were miscoded by RCUI.
RCUI database is acceptably complete and accurate for non-invasive bladder
cancers identiﬁ  ed from DGH. DGH coding of non-invasive bladder cancers
is not as consistent or accurate as RCIU. Nationally agreed coding practices
would be beneﬁ  cial.
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SINGLE CENTRE EXPERIENCE OF OXALIPLATIN (L-OHP) FOR 
ADVANCED COLORECTAL CARCINOMA (ACC) IN THE WAKE
OF NICE
C Thomas, Z Kassam, R Glynne-Jones, M Harrison
Mount Vernon Cancer Centre, London, United Kingdom
INTRODUCTION: 5-year survival of patients with ACC with
unresectable  liver metastases is 3%. 5-year survival o f 20 to 45%
has been reported with surgical resection of hepatic metastases.
Neoadjuvant chemotherapy may enable liver resectionin patients who
are initially unresectable andlong-term survival is similar to that of a
priorisurgical candidates.In March 2002 NICE issued guidance that L-
OHP in combination with 5 Fluorouracil/folinic acid (5FU/FA) should 
be considered as ﬁ  rst line therapy in ACC with metastases conﬁ  ned to
the liver that may become resectable. We present our experience.
METHODS: 41 patients with ACC with liver metastases in whom L-
OHP/5FU/FA was planned were prospectively entered into a pharmacy
database between 1st March 2002 and 1st February 2004.
RESULTS: Mean age was 60 years (32-78), with M:F of 1.5:
1.Synchronous:metachronous liver metastases was 3:1. 36 (88%)
patients have completed chemotherapy to date and been restaged. Of 
these 15 (42%) had a partial response, 9 (25%) had stable disease, and 
12 (33%) progressive disease (using the RECIST criteria). Of these
36 patients 21 (58%) patients were referred for consideration of liver 
resection. 6 (17%) patients underwent successful liver resection, 1
patient was found to have unresectable disease at laparotomy, 9 were
turned down and 5 are awaiting an opinion. Mean follow up from the
start of chemotherapy was 14 months (2.0-22). 10 patients (24%) have
died, including 1 patient 10 months following hepatic resection, with
a mean time to death from the start of chemotherapy of 9.25 months.
Median survival has not been reached.
CONCLUSION: In our cohort L-OHP/5FU/FA produced a PR in 42%
and a hepatic resection rate of 17%. Chemotherapy to ‘downstage’
unresectable hepatic metastases has an important role to play in the
management of ACC, as surgical resection offers the only chance of 
cure.
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POSITRON EMISSION TOMOGRAPHY (PET) IN POTENTIALLY 
OPERABLE METASTATIC COLORECTAL CANCER PATIENTS:
DOES IT ALTER THE DECISION TO OPERATE?
LM Samuel, M Brooks, V Duddalwar, M Koruth 
Aberdeen Royal Inﬁ  rmary, Aberdeen, United Kingdom
Introduction
The 5 year survival for patients with metastatic colorectal cancer (CRC)
conﬁ  ned to the liver who have hepatic resection is 40%, suggesting many
have  occult metastatic  disease. PET scans  can  detect  occult metastatic
disease, and improve selection for liver surgery, with some studies suggesting
a 70% 3-year survival by using PET.
Aims
To prospectively assess the value of PET scanning by looking initially at
alterations in treatment decisions when PET scan result revealed. 
Methods
All eligible patients, who had no obvious extra-hepatic metastases on
abdo-pelvic CT & CXR, had conventional staging (CT angio-portography,
and thin slice thoracic CT scan) and a whole body FDG PET scan. PET
reported by a radiologist unaware of other staging results. Initial surgical
decision taken & recorded without prior knowledge of PET result and then
re-assessed with PET result.
Results
First six months results available: 12 eligible patients, of w hom 7 have
gone on to have a liver resection. Two of these patients had small volume
lung metastases detected but this was felt to be potentially resectable at a
later date (successfully completed in one patient). Of those not going on
to liver resection, one patient with two tiny lesions had a negative PET and
has been kept under close review since. Four had extensive disease detected,
including two new primaries detected by PET scanning and conﬁ  rmed at
colonoscopy.
Conclusion
PET scanning altered the decision to operate in 40% of patients, sparing
them unnecessary liver surgery, and the NHS the costs associated with this
type of surgery. The results are in keeping with similar small studies. A
health economic analysis is planned.
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COMPLIANCE TO CHEMOTHERAPY WITH OXALIPLATIN AND 
5FLUOROURACIL IN PATIENTS WITH ADVANCED RECTAL
CANCER WHO HAVE RECEIVED PRIOR HIGH-DOSE PELVIC
RADIOTHERAPY
A Makris 1, R Glynne-Jones 1, D Sebag-Monteﬁ  ore 2, L Samuel 3,
S Myint 4, E Levine 5, A Martin 1, J Dixon 1
1 Mount Vernon Hospital, Northwood, United Kingdom, 2 Cookridge
Hospital, Leeds, UK, 3 Aberdeen Royal Inﬁ  rmary, UK, 4 Clatterbridge
Hospital, Wirral, UK, 5 Christie Hospital, Manchester, UK
Pelvic radiotherapy  (RT) may compromise the compliance and 
effectiveness of future chemotherapy (CT).
20 patients (15 male, 5 female), mean age 69 yrs (range 51-75) were
studied in a prospective, multicenter, phase II study. All patients had 
recurrent or metastatic diease. All had received previous pelvic RT:
45Gy 25 fx (15), 45 Gy 30 fx (3), 45 Gy 20 fx (2) and 25 Gy 5 fx (1) at
a 16 months prior to this study. Most patients had received concurrent
chemoradiation (CRT). Patients were treated with a schedule consisting
of oxaliplatin 85 mg/m2on day 1 and 5FU 400 mg/m2iv bolus and 600
mg/m2iv 22hour infusion with folinic acid on day 1 and 2. A maximum
of eight cycles of CT were administered every two weeks.
A median number of 7 cycles of CT was given  (range 3-8), with
132 cycles being given in total. There were 8 episodes of grade III
neutropaenia (1 with sepsis). There were 4 episodes of grade III/IV
diarrhoea, two of which required hospitalisation, but all resolved. In 18
evaluable patients patients the overall response rate was 33% (3 CR; 3
PR), with 2 patients having SD.
This study shows that the combination of oxaliplatin, 5FU and folinic
acid after high-dose pelvic RT is well tolerated and has comparable
efﬁ  cacy to that seen in other metastatic studies and a dose intensity
equal to that achieved in adjuvant studies. Based on the results of this
study, adjuvant oxaliplatin is being delivered in a randomised phase III
study (CHRONICLE) following CRT.
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MINICHROMOSOMAL MAINTENANCE PROTEINS (MCMS)
AS A POTENTIAL NEW TOOL FOR DIAGNOSIS OF PROSTATE 
CANCER
JL Watkins 1, T Bailey 1, H Clark 2, J O’Donnell 2, AC Woodman 1
1 Cranﬁ  eld Biomedical Centre, Cranﬁ  eld University, Silsoe, United 
Kingdom, 2 Department of Biochemistry, Northampton General 
Hospital NHS Trust, Northampton, United Kingdom
Prostate cancer is now the most prevalent cancer in men accounting
for 20% of all new cancer cases and 12% of cancer deaths in the
UK.  Current diagnostic tests for the disease include measurement of
serum PSA (prostate speciﬁ  c antigen) and digital rectal examination
(DRE).  These techniques may however be problematic, especially since
evidence suggests that PSA is not prostate speciﬁ  c and is affected by a
variety of factors including age, sexually activity and life style. 
This study aimed to investigate speciﬁ  city of PSA expression by
assessing PSA production in a number of prostatic and non-prostatic
cell lines in vitro, and to consider MCMs as alternative markers for
prostate disease. Cell lines derived from eight different tissue types
were examined using both immunocytochemistry and western blotting,
with antibodies to PSA and MCM-2, -5 and -7. 
The results show that PSA is produced by a number of cell lines,
including those derived from prostate, colon, bladder and oral
epithelium, providing further evidence that PSA is not prostate speciﬁ  c.
As an alternative marker, MCMs show differences in the intensity of
expression and locality of expression, when cell lines derived from
normal prostate and cancerous prostate tissue were examined.
Due to an increasing body of evidence including the results of this
study, the measurement of serum PSA may be providing misleading
information in the diagnosis of diseases of the prostate.  Our study also
shows that MCMs may be a novel molecular marker for prostatic cancer,
but further work needs to be performed on tissue, to conclude whether
MCMs will be a useful diagnostic tool.
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PHOTODYNAMIC THERAPY FOR PROSTATE CANCER – A
NOVEL TECHNIQUE FOR ASSESSING LIGHT TRANSMISSION 
IN THE PROSTATE
CM Moore 1, CA Mosse 1, I Hoh 1, H Payne 2, D Rickards 3,
SG Bown 1, ME Emberton 4
1 United Kingdom, National Medical Laser Centre, University
College London, London, 2 United Kingdom, Myerstein Institute of 
Oncology, University College London Hospitals Trust, London, 3
United Kingdom, Department of Imaging, University College London 
Hopsitals Trust, London, 4 United Kingdom, Institute of Urology, 
University College London, London
Aims
Photodynamic therapy (PDT) uses a light activated drug to cause necrosis, whose
depth depends on the penetration depth (PD) of light. Previous studies have
measured PD in up to three positions per prostate with wavelengths of up to 665
nm. These wavelengths can be absorbed by haemoglobin, leading to large variation
in PD. Newer drugs are activated by light of longer wavelengths. It is predicted that
they will have increased PD, and will not be absorbed by haemoglobin. We aimed 
to use a novel technique to determine PD in multiple positions throughout the
prostate, with 763nm light.   
Procedures
Patients having high dose rate (HDR) brachytherapy for prostate cancer have
multiple transparent plastic needles in the prostate for two days. These are used 
to carry radioactive iridium wires but are also suitable for carrying optical ﬁ  bres.
Laser light was delivered along the needles using a cylindrically diffusing optical
ﬁ  bre.  An isotropic detector was placed sequentially in nearby needles, and optical
power at different distances from the source was measured with a light meter.
Needle separation was measured on CT.
Major ﬁ  ndings
PD is the depth at which 63% of light intensity is lost. It is calculated from the
diffusion theory approximation to the Boltzmann transport equation. The mean
PD over 600 readings was 5.5mm ( 2.7-12.1mm).
Signiﬁ  cance
The PD showed greater variability than expected. 
g
The PD showed greater variability than expected. 
g
As this variation is proportional
to the depth aimed to treat, absolute variation will need to be minimised by
reducing the needle separation to less than ten mm.
Conclusion
PDT for prostate cancer will require multiple interstitial light sources, similar to
the needle conﬁ  guration used for HDR brachytherapy.
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PHOTODYNAMIC THERAPY FOR PRIMARY PROSTATE
CANCER – A PILOT STUDY USING MTHPC
CM Moore 1, TR Nathan 1, WR Lees 2, A Freeman 3,
CA Mosse 1, M Emberton 4, S G Bown 1
1 United Kingdom, National Medical Laser Centre, University 
College London, London, 2 United Kingdom, Department of Imaging, 
University College London Hospitals Trust, London, 3 United 
Kingdom, Department of Histology, University College London
Hospitals Trust, London, 4 United Kingdom, Institute of Urology,
University College London, London
Aims
To determine whether photodynamic therapy (PDT) using meso tatra hydroxy
phenyl chlorin (mTHPC) could be a primary treatment for organ conﬁ  ned
prostate cancer.
Procedures
Six men with histologically proven prostate cancer, who were unsuitable for or
declined radiotherapy, surgery or active surveillance were studied. The mean
pre-treatment PSA was 7.7 ng/ml (range 2.7-15), with a Gleason score of 3 + 3
in all patients.
The photosensitiser mTHPC was given intravenously and activated after 2
–5 days by 652nm light delivered transperineally to the prostate using MRI
guidance. Areas of cancer were treated under local anaesthetic and sedation
according to MRI or biopsy results. The peripheral zone of the same lobe was
also treated. 4 out of 6 patients had 2 treatments.
Major ﬁ  ndings
Early MRI changes indicated extensive oedema, with patches of ill deﬁ  ned
necrosis. This necrosis was well deﬁ  ned at 1 month and was not seen at 3
months. Histology revealed areas of necrosis and  ﬁ  brosis at 1 month and
ﬁ  brosis at 2 months. 8 out of 10 treatments resulted in a PSA reduction (mean
reduction per patient 4.0 ng/ml, range –2.0 - 10).
2 treatments led to catheterisation for 9 and 19 days respectively. 1 patient
had incontinence requiring 1 pad per day for 4 months following a 2nd PDT d
treatment. 
Signiﬁ  cance
This is the ﬁ  rst report of the use of PDT as a primary treatment for prostate
cancer. Necrosis followed by ﬁ  brosis, and a PSA reduction were seen. 
Conclusion
PDT for primary prostate cancer merits further investigation.
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CASE ASCERTAINMENT IN PROSTATE CANCER STUDIES-HOW 
RELIABE ARE HISTOPATHOLOGY DATABASES ALONE?
S Evans 1, C Corbishley 2, G Muir 3, D Gillatt 4, Y Ben-Shlomo 5,
R Persad 5
1 United Kingdom, Department of Social Medicine, University of 
Bristol, Bristol, 2 United Kingdom, St.George’s Hospital, London, 3
United Kingdom, King’s College Hospital, London, 4 United Kingdom,
Southmead Hospital, Bristol, 5 United Kingdom, Bristol Royal 
Inﬁ  rmary, Bristol
Introduction
Identifying all patients with a speciﬁ  c cancer diagnosis in a hospital is essential to
perform accurate clinical audit and for precise registry reporting. The objective of 
this study was to determine how many cases of prostate cancer would be missed if 
only histopathology databases were the source of case identiﬁ  cation.
Patients and Methods 
As part of an ongoing cohort study of men with prostate cancer, all eligible
histological and c linically  diagnosed cases of prostate cancer were sought at
four UK hospitals. Multiple hospital databases were reviewed: Histopathology,
Patient Administration System (PAS) and Biochemistry (PSA  10ng/ml). Case
summaries of all patients with a possible or probable clinical diagnosis of prostate
cancer were reviewed by a panel of six Consultant Urologists to determine whether 
there was sufﬁ  cient evidence for a clinical diagnosis of prostate cancer.
Results
Of a total of 1201 cases identiﬁ  ed, 95% had a histological diagnosis, and 5% a
clinical diagnosis of prostate cancer. Additional cases (n=147) identiﬁ  ed from
PAS and PSA database review constituted 12.2% of the total cohort. 89 of these
cases were subsequently found to have positive histology not recorded on the
histopathology databases. The original histopathology databases would have only
identiﬁ  ed 88% (95% CI 85.8 to 89.6) of all the cases and 92.2% (95% CI 90.5 to
93.7) of those cases with a histological diagnosis.
Conclusion 
Multiple-source case ascertainment ensures that all cases of  prostate cancer 
are identiﬁ  ed. Hospital studies relying on a single histopathology database may
signiﬁ  cantly underestimate the true number of cases managed in their unit. This
may a lso result  in a signiﬁ  cant under-reporting o f prostate cancer to Cancer 
registries.
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THE ACUTE URINARY TOXICITY OF COMBINED HIGH DOSE
RATE BRACHYTHERAPY BOOST AND EXTERNAL BEAM 
IRRADIATION FOR HIGH RISK PROSTATE CANCER           
NA Anyamene, O Severn, D D’Souza, J Solano, HA Payne
Meyerstein Institute of Oncology, London, United Kingdom
INTRODUCTION-A high proportion of patients who present with
prostate cancer in the UK have intermediate or high risk disease. There are
encouraging results in the USA and Europe for radiotherapy dose escalation
using a combination of external beam radiotherapy (EBRT) with a high
dose rate (HDR) brachytherapy boost for this group of patients. We present
the acute urinary toxicity for the ﬁ  rst 30 patients treated at our centre in
London.
METHODS- Entry criteria were any of: stage T3a N0 M0, Gleason grade
>8, PSA >20. Patients were initially treated with an HDR boost. Applicator
needles were inserted through a perineal template with the aid of transrectal
ultrasound. The treatment volume was CT planned and the dose given by
an iridium HDR afterloading MicroselectronTM. The prescribed dose was
16.5Gy in 3 fractions with a minimal interfraction interval of 6 hours. EBRT
(46Gy in daily 2Gy fractions) was given to a CT planned volume of prostate
and periprostatic tissues.
RESULTS- The age range was between 52 and 79 years (mean = 65years)
70% stage T3a, 76% Gleason grade >8, 40% PSA >20). All had a minimum
of 6 months follow up from completion of radiotherapy (range 6-46 months).
Acute urinary toxicity was graded using the Mameghan scoring system.
Grade 2 urinary toxicity at the end of brachytherapy was nocturia 33%,
haematuria 0%, incontinence 7%, dysuria 10% with Grade 1 toxicity nocturia
17%, haematuria 7%, incontinence 3%, dysuria 33%. At the end of EBRT
Grade 2 toxicity was nocturia 20%, haematuria 0%, incontinence 3% dysuria
50%, with Grade 1 toxicity nocturia 50%, haematuria 3%, incontinence 7%,
dysuria 20%. At 3 and 6 months after completion the urinary morbidity was
identical to that measured in the pre-treatment assessment.
CONCLUSION- Brachytherapy  boost  in combination with EBRT is
well tolerated with small risks of Grade 2 toxicity immediately after the
procedure. The side effects rapidly reduce with no additional toxicity at 3
and 6 months after completion of all treatment
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ANALYSIS OF NEP AND ECE-1 METALLOPROTEINASE
EXPRESSION IN PROSTATE CANCER TISSUE MICROARRAYS
E Leah, AJ Turner, BA Usmani 
University of Leeds, Leeds, UK
Prostate Cancer (PC) cells which survive androgen withdrawal
therapy can switch allegiance to alternative growth pathways, fuelled 
by mitogenic peptides, which are normally inactivated by zinc
metalloproteinases belonging to a small family of Neprilysin (NEP)-
like enzymes. In human PC, NEP loss is recognised as contributing to
metastatic androgen-independent PC progression by allowing mitogenic
peptides such as endothelin-1  (ET-1) to stimulate cell proliferation.
ECE-1, a close homologue of NEP, generates active endothelin (ET-
1). We have shown that highly metastatic, androgen-independent PC
cell lines express high levels of ECE-1 whereas little ECE-1 is seen in
poorly metastatic, androgen-sensitive LNCaP cells. We have also shown
a tight inverse correlation between PC expression of NEP and ECE-1.
In this study, analysis of archive patient PC tissue microarrays revealed 
54% high grade and 19% low grade patient tumours expressed ECE,
whereas 15% high grade and 25% low grade tumours expressed NEP.
ECE-1 is recognised to exist as four isoforms a,b,c,d. ECE-1c appears
to be the common isoform present on cell membranes both in epithellia
and stroma of highly malignant tumours. On the other hand, ECE-1a has
been unexpectedly recognised in the nucleus of malignant cells and the
signiﬁ  cance of this remains to be explored. Interestingly, TMA cores
representing benign prostatic hyperplasia (BPH) revealed mainly NEP
expression (81%).
Conclusion: the data presented here shows an inverse correlation
between NEP and ECE-1 in prostate TMA’s. This data needs to be
correlated with remaining clinical evidence, such as PSA levels,
Gleason score, AR status etc, in order to identify a value for ECE and 
NEP as prognostic or therapeutic markers for prostate cancer.
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DO PROSTATE CANCER PATIENTS AND THEIR CARERS HAVE 
A REALISTIC KNOWLEDGE OF THE EPIDEMIOLOGY OF
PROSTATE CANCER?
S Evans 1, K Anson 3, G Muir 4, B Patel 1, R Persad 1, Y Ben-Shlomo 1
1 United Kingdom, Department of Social Medicine, University of 
Bristol, Bristol, 2 United Kingdom, Bristol Royal Inﬁ  rmary, Bristol,
3 United Kingdom, St.George’s Hospital, London, 4 United Kingdom,
King’s College Hospital, London
Introduction
There is little information on the lay epidemiology of prostate cancer. The
objective of this cross-sectional survey was to determine knowledge of the
epidemiology of prostate cancer amongst men with prostate cancer or their
carers.
Patients and Methods
Prostate cancer patients or their carers (in the case of deceased patients) were
sent a questionnaire within an ongoing historical cohort study of multi-ethnic
communities in the UK. This included several questions on the epidemiology
of prostate cancer as well as detailed socio-demographic variables from which
a score for socioeconomic status (SES) was derived.
Results
Absolute risk of prostate cancer was over-estimated so that 64% of the sample
(n=271) believed that amongst men over 65 years of age annual risk of prostate
cancer diagnosis was 10% or more. Higher SES was associated with a greater
knowledge of the absolute and relative risk of prostate cancer. Subjects were
asked if Black men had a greater, lesser or similar risk of disease compared to
White men. 80% of Black men felt that there was no ethnic difference or the
risk may even be less for Black men. Risk factors chosen in order of popularity
were age, family history and smoking. More afﬂ  uent subjects favoured family
history whilst smoking, despite no convincing epidemiological evidence, was
more likely to be chosen by poorer respondents.
Conclusions
The perceived risk of prostate cancer was overestimated. Most Black men,
however, did not seem to be aware that they may have been at a greater risk of
being diagnosed with prostate cancer. Comparisons with healthy population
samples are needed to highlight  future educational needs around prostate
cancer awareness.
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ACUTE URINARY MORBIDITY DURING CONFORMAL
RADIOTHERAPY FOR PROSTATE CANCER
S Evans 1, R Jones 1, J Graham 2, R Persad 1
1 United Kingdom, Bristol Royal Inﬁ  rmary, Bristol, 2 United Kingdom,
Bristol Haematology & Oncology Centre, Bristol
Introduction 
Although  long-term urinary toxicity  from radical t hree-dimensional
conformal radiotherapy (3D-CRT) for localised prostate cancer appears
limited, there remains a strong clinical impression of a transient increase
in urinary symptoms and deterioration in quality of life (QoL) during
treatment. The objective of this study was to determine the immediate
effects of 3D-CRT for prostate cancer on lower urinary tract symptoms
and QoL.
Patients and Methods 
24 consecutive patients with localised prostate cancer were recruited 
into a prospective study in which the International Prostate Symptom
Score (IPSS) and American Urological Association QoL score were
serially recorded from baseline, weekly during 3D-CRT, and at four and 
eight weeks following the end of treatment.
Results
Mean IPSS (0-7mildly symptomatic; 8-19 moderately symptomatic;
20-35 severely symptomatic) rose from 9.75 at baseline to 20.2 by the
end of radiotherapy (95% CI for difference 6.3 to 14.6, p<0.001). 50%
of patients developed “severe” urinary symptoms by IPSS classiﬁ  cation
compared to only 10% at baseline. Mean AUA QoL score due to urinary
symptoms (0=“delighted” to 6=“terrible”) demonstrated a comparable
pattern of  deterioration  from 2.3 at baseline to 3.9 by the end o f 
treatment (95% CI for difference 0.9 to 2.2, p<0.0001). By eight weeks
post-radiotherapy mean IPSS and QoL score had returned to baseline
levels.
Conclusions
3D-CRT for localised prostate cancer is associated with a signiﬁ  cant
acute and transient rise in the IPSS and deterioration in QoL. Further 
studies to explore the aetiology and possible prevention of these
signiﬁ  cant symptoms are warranted.
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EPIGENETIC INACTIVATION OF THE HSPRY2 GENE IN HUMAN
PROSTATE CANCER
AB McKie, DA Douglas, S Olijslagers, JM Graham, MM Omar,
CN Robson, HY Leung
Univ. of Newcastle, Newcastle, United Kingdom
Fibroblast growth factors (FGFs) and their receptors are key modulators
of normal prostate proliferation with their over-expression associated
with aggressive prostate cancer (CaP) and  less  favourable survival
outcome. Recent studies have highlighted the importance of negative
regulation of  growth  factor signalling s ystems through mechanisms
involving the ubiquitin  ligase c-Cbl and  inhibitory proteins such as
Sprouty.
Quantitative RT-PCR was carried out on a cohort of resected CaP and
BPH specimens: high  grade  (poorly differentiated) CaP expressed
Spry2 at signiﬁ  cantly lower levels than both BPH and well differentiated
tumours (p= 0.004). We therefore hypothesise that the observed reduced
Spry2 expression is related to the process of prostate carcinogenesis.
The hSPRY2 gene maps to the long arm of chromosome 13 with CGH
and LOH studies  implicating  genetic  loss associated w ith CaP. The
existence of a large CpG island (OBSCpG/EXPCpG ratio of 0.92) led us
to investigate the possibility of epigenetic inactivation at this locus.
p p
Treatment of LNCaP and PC-3M cells with 5-aza-2’-deoxycytidine
(Aza dCR) led to an increase in Spry2 expression from barely detectable
levels to moderate  levels. Using a combination of methylation
speciﬁ   c PCR, and direct sequencing, we have observed extensive
hypermethylation of the CpG island in 85% of high grade CaP cases
(n=21). Seven control cases of benign prostatic hyperplasia (BPH) were
however unmethylated.
Furthermore, selected CaP tumors with reduced Spry2 expression in
quantitative RT-PCR were shown to be extensively h ypermethylated
and control BPH cases with  high  levels of Spry2 expression were
unmethylated. Extensive SSCP analysis  yielded little evidence of
mutation within the hSPRY2 gene, however 40-47% LOH was observed
with close ﬂ  anking marker D13S1277 extending distally to D13S266.
Posters
S36
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP51
SOLUBLE FGFR (SFGFR) SYNERGISES WITH PACLITAXEL AND
GAMMA-IRRADIATION IN SUPPRESSING HUMAN PROSTATE
CANCER GROWTH IN VITRO
B Gowardhan, C.N. Robson, H.Y. Leung
Prostate Research Group, School of Surgical and Reproductive
Sciences, Newcastle University, Newcastle upon Tyne,
United Kingdom
The  ﬁ  broblast growth factor (FGF) family is implicated in prostate
cancer, making them important targets for therapeutic agents. sFGFR 
is the extra-cellular domain of the native FGF receptor (FGFR) which
suppresses in vitro FGF induced cellular signalling and function. We
studied the in vitro effects of combining sFGFR gene therapy with
paclitaxel and gamma-irradiation.
Proliferation and colony formation of DU145 cells were assessed using
recombinant adenoviruses coding for sFGFR1iiib (AdIIIcR1) at a dose
of 100 viral particles per cell and various doses of paclitaxel and gamma
irradiation. 
Proliferation of AdIIIcR1  infected DU145 cells was suppressed  by
45% when combined with paclitaxel at 2.5nmol/ml compared to
1% for controls (p=0.005). Similarly, colony formation in AdIIIcR1
infected cells was suppressed by 99% when combined with 1nmol/ml
of paclitaxel compared to 40% for controls (p=0.0007). Proliferation of 
AdIIIcR1 infected cells was suppressed by 45% when combined with
gamma irradiation at 2Gy compared to 8% for controls (p=0.0003).
Similarly, colony formation in AdIIIcR1 infected cells was suppressed 
by 50% when combined with 2Gy of gamma irradiation compared to
13% in controls (p=0.0001).
In conclusion, sFGFR synergises with paclitaxel and gamma irradiation
in suppressing proliferation and colony formation of DU145 cells.
It therefore is a promising agent in the treatment of prostate cancer 
which may help reduce the dose of chemo- and radio- therapy without
compromising on attaining the desired therapeutic effect.
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PROSTATE CANCER – HORMONES FIRST, RADIOTHERAPY 
LATER, OR LATER STILL
KJ Turner, C Parsons, SA McNeill, D McLaren
Western General Hospital, Edinburgh, United Kingdom
Introduction and Aims: Contemporary treatment for locally advanced
prostate cancer (PC) includes external beam radiotherapy (EBRT) with
concomitant androgen ablation. We have a cohort of patients who were
treated with prolonged androgen ablation prior to radical EBRT. The
outcome of such an approach has not been evaluated previously.
Patients and Methods: Patients with PC who had been treated with
androgen ablation for at least 10 months prior to radical EBRT were
identiﬁ  ed  from our EBRT database. Baseline tumour characteristics
were recorded and outcome variables including time to progression and
time to death following EBRT were obtained from notes review. Data
were analysed by Cox regression analysis.
Results: 45 eligible patients (mean age 67 years) were diagnosed
between 1969 and 1999. Mean follow up was in excess of 7 years (86
months (range 36-192) months. Mean duration of androgen ablation
prior to EBRT was 40 months (range 10-84 months). Overall 5-year
progression free survival was 36%. PSA nadir on androgen ablation
prior to EBRT, and PSA nadir post EBRT were both s igniﬁ  cantly
associated with prolonged progression free survival (p=0.03 and
p=0.01 respectively). PSA at diagnosis was not a signiﬁ  cant predictor
of outcome. A shorter duration of androgen ablation prior to EBRT was
associated with signiﬁ  cantly prolonged progression free and overall
survival (p=0.03 and p=0.01 respectively).
Conclusions: The optimal sequence, timing, and duration of androgen
ablation  in patients with PC undergoing EBRT with curative  intent
remain undetermined. Results presented here compare favourably with
results for early EBRT and androgen ablation in high risk PC. A shorter
period of androgen ablation and good biochemical response to androgen
ablation and EBRT are associated with better outcome. A prolonged
period of hormone ablation should not necessarily exclude PC patients
from receiving potentially curative radical EBRT.
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ISSUES OF DOSIMETRIC ANALYSIS OF BRACHYTHERAPY
SEED IMPLANTS
D Power, I Coles, K Wood, S Stewart
United Kingdom, Charing Cross Hospital, London
Introduction: Prostate brachytherapy  in early prostate carcinoma  in
appropriately selected patients achieves comparable survival and local
control rates to radical surgery/radiotherapy. The dose delivered to 90%
of the prostate gland (D90) correlates with clinical outcome.
Methods: 71 patients were treated with palladium-103 seed implant
between January 1999 and 2003. Implant quality audited using
American Brachytherapy Guidelines (1999). Post implant dosimetry
using Computerised Tomographic imaging was calculated using MMS
Planning System (Variseed). Rectal dose volume histograms (RDSH)
and urethral doses also assessed. 
Results: Average age 61 years (range: 48 - 73). Average number of Pd-
103 seeds implanted = 77 (55-106). Pre-treatment ultrasound assessed 
prostate volumes: 82%  40cm3, 0%  60cm3. Signiﬁ  cant differences
observed  in the pre implant ultrasound & post implant CT deﬁ  ned 
prostate V100 & V200.  Ratio of U ltrasound  prostate volume: CT
prostate volumes = 1.45. D90 adequate in 60% of patients analysed. 
Discussion: Difﬁ  culty outlining post-implant prostate gland using CT
imaging is well recognised. Implant quality assessment is dependent
on accurate prostate volume deﬁ  nition. This is difﬁ  cult to deﬁ  ne with
the use of differing imaging modalities pre and post implant. No clear 
correlation between rectal dose surface histogram and rectal toxicity.
Assessment of rectal dose practically difﬁ   cult. We also identiﬁ  ed 
problems localising urethra using current imaging techniques in the
assessment of urethral dose. 
Conclusions: Variations in imaging modalities pre and post implants
results in difﬁ  culties in dosimetric analysis, reﬂ  ected in the V100 & D90
values. Important to audit adequacy of prostate brachytherapy implant
technique. Rectal and urethral dose assessment difﬁ  cult with current
imaging techniques. There are currently no clearly deﬁ  ned national
standards to audit against.
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WEIGHT TRAINING HAS BENEFICIAL PHYSICAL AND 
PSYCHOLOGICAL EFFECTS IN PROSTATE CANCER (PC)
PATIENTS ON ANDROGEN DEPRIVATION THERAPY (ADT)
NSA Stuart 1, SM Marcora 1, N Callow 1, SJ Oliver 1, W Saxton 2
1 United Kingdom, University of Bangor, Bangor, 2 United Kingdom,
Gwynedd Hospital, Bangor
Background: ADT is the standard treatment for metastatic prostate cancer.
However it also causes muscle wasting, fatness, bone loss, fatigue, and
reduces physical activity and quality of life (QoL). The aim of this pilot
study was to assess the feasibility and effectiveness of progressive resis  tance
training  (PRT,  “weight training”) in reducing or reversing these effects.
Methods: 10 PC patients (pts) on ADT were randomly allocated either to
supervised PRT in the University gym 3 times/week for 12 weeks (training
group TG, n=5) or standard treatment alone (control group CG, n=5). Pts
were assessed before randomisation and after 12 wks. Physical measures
were body composition (measured by DEXA scan), Senior Fitness Test
and ped  ometry. Psychological measures were Bidimensional Fatigue Scale,
FACT-Prostate QoL scale and HAD scale.  Results  (physical):  One TG
subject was dropped from the study for safety reasons (diagnosis of bone
metastases shortly after enrolment). The other 4 pts completed 85% of
the training sessions. There was a increase in total muscle mass in the TG
(2.2 ±1.1 kg) compared to the CG (-0.1 ±0.7 kg, p = 0.02).  This was
particularly evident in the arms and legs. These changes were not solely
due to an increase in extra-cellular water but also intra  cellular water and
protein mass.  There were also improvements (p = 0.02) in upper body
strength and lower body ﬂ   exibility as well as non-signiﬁ   cant trends to
improvements in physical activity, agility and 6-minute walking distance.
Results  (psy  chological): In the TG compared w ith t he CG there were
statistically non-signiﬁ  cant trends to improvement in FACT-P (+5.3 points vs
–10.4), BFS and HADS.  Conclusion: PRT is an effective and well tolerated
treatment for the adverse physical effects of ADT. It may also reduce the
adverse psychological effects. An application has been made to CR(UK)
to  fund a larger, randomised, controlled study to conﬁ  rm  these results.
A work out in the gym may become an important part of the palliative care
of PC pts.
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QUANTITATIVE PROTEOMIC ANALYSIS OF ANDROGEN &
ANTI-ANDROGEN RESPONSES IN THE LNCAP PROSTATE 
CANCER CELL LINE
JG Rowland 1, JW Simon 2, AR Slabas 2, CN Robson 1, HY Leung 1
1 University of Newcastle upon Tyne, Newcastle upon Tyne, United 
Kingdom, 2 University of Durham, Durham, United Kingdom
Introduction.   Proteins responsive to androgen and anti-androgen may
be involved in the development of prostate cancer and the ultimate failure
of androgen-ablation therapy. These proteins are potential targets for the
development of novel therapeutic agents. We have investigated the effect
of androgen and anti-androgen stimulation on the androgen responsive
prostate cancer LNCaP cell  line using 2-dimensional  differential  in-gel
electrophoresis technology (2-DIGE), with the aim of discovering proteins
involved in the androgen receptor function in LNCaP cells.
Methods.   Primed LNCaP cells were stimulated with 10nM R1881, 1µM
bicalutamide or vehicle (ethanol) for 72hrs. Cells were harvested and lysed 
in IEF buffer (9M Urea, 2M Thiourea, 4% CHAPS). Three biological repeats
were generated and analysed using 2D-DIGE technology  (Amersham
Biosciences). Samples were labelled with CyDye ﬂ  uors, multiplexed and 
subjected to 2-dimensional electrophoresis (pI range 3-10, linear). Gels were
imaged using a Typhoon laser scanner and analysed in the DeCyder software
package (Amersham Biosciences). Differential expression was determined 
by student’s t-test and >1.5-fold change in abundance.
Results. Gels containing around 3000 protein features per gel were produced,
with 77 protein spots showing signiﬁ  cant differential regulation, including
proteins  involved  in protein synthesis, antioxidant  defence and various
signalling pathways. Many have previously been reported to be androgen-
responsive or potentially involved in the development and progression of 
malignancies including prostate cancer.
Conclusion. Using 2D-DIGE we have quantitatively identiﬁ  ed numerous
candidate proteins involved in the cellular response to androgens and anti-
androgens. These proteins may be targets for the  development of novel
therapeutic intervention strategies.
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ANORECTAL DYSFUNCTION AFTER RADIOTHERAPY FOR 
UROLOGICAL MALIGNANCY
D Hayne, BK Somani, RS Kushwaha, E Wrightham,
H Payne, PB Boulos 
1 City Hospital, Birmingham, United Kingdom, 2 The Middlesex 
Hospital, London, United Kingdom, 3 Department of Surgery,
Royal Free and University College Medical School, London, United 
Kingdom, 4 The Meyerstein Institute, London, United Kingdom
The adverse effects of pelvic radiotherapy on anorectal function may be
underestimated. This prospective study aimed to identify symptoms
31 men (median age 70 years) with carcinoma of the prostate (28)
and  bladder  (3) completed  incontinence/proctitis symptom scores
and anorectal physiological studies before and 6 weeks after pelvic
radiotherapy. At 6 months 19 of these patients were studied. Results
were compared using the Wilcoxon signed rank test.
Incontinence scores increased: 0 (0-5) v 4 (0-11) (p<0.001) v 3 (0-14)
(p<0.007), pre v 6 weeks post- v 6 months post-radiotherapy, median
(range) and proctitis scores increased: 0 (0-4) v 2 (0-7) (p<0.001) v
2 (0-5) (p<0.004), pre v 6 weeks post- v 6 months post-radiotherapy,
median (range).
Anal canal resting pressure decreased:  83 (35-137) v 79 (26-152)
(p<0.136) v 73 (37-97) (p<0.001), pre v 6 weeks post- v 6 months post-
radiotherapy, median cm H2O (range), squeeze pressure was unchanged
but maximum tolerated rectal volumes decreased: 245  (115-450) v 194
(112-344) (p<0.005) v 194 (109-350) (p<0.005), pre v 6 weeks post- v
6 months post-radiotherapy, median cm mls (range). 
Signiﬁ  cant acute symptomatic and manometric anorectal disturbance
is seen after RT for  prostate and  bladder cancer. At six weeks this
appears to be related to diminished maximum rectal tolerated volumes.
Symptoms at 6 months may be explained by the decrease in anal canal
resting pressure together with diminished maximum rectal tolerated
volumes.
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ACUTE RECTAL TOXICITY AFTER CONFORMAL 
RADIOTHERAPY FOR PROSTATE CANCER. COULD V 50 V 50 V  OR AUC
OF A DVH BE PREDICTIVE FACTORS
NA Anyamene, O Severn, R Subramaniam, HA Payne
Meyerstein Institute of Oncology, London, United Kingdom
Purpose & Objectives: The volume of the rectum (as deﬁ  ned by the DVH)
receiving the prescribed radiation dose is a well described predictive (and 
dose limiting) factor of late toxicity following treatment for prostate cancer.
There is, however, little literature on predictive factors for acute rectal
symptoms. We aim to identify whether there is a relationship between
AUC (area under curve) of the rectal DVH (dose volume histogram) or 
V50 (volume of rectum receiving 50Gy) and acute rectal toxicity after CT
conformally planned radiotherapy for prostate cancer.
Methods: We prospectively analysed 20 consecutive patients with T1-
T3 adenocarcinoma of the prostate treated between August –September 
2003. Median age 62 years (range 49-77). They received CT conformally
planned external  beam radiotherapy to an IRCU dose of 74Gy. The
rectum was outlined from 1cm  above and 1cm below the GTV (gross
tumour volume) and included the outer rectal wall. The V50 and AUC were
identiﬁ  ed from the rectal DVH.
  Acute anorectal symptoms were assessed at the end of treatment and one
month post completion using a 0-11 score questionnaire devised by Talley
et al 1997. We looked for a  correlation between symptom scores at these
times and the V50and AUC.
Results: The mean anorectal toxicity score at the end of treatment was
3.68 (range 0-7) and at one month post completion of treatment was 0.52
(range 0-2). The mean V50 was 42.31% (range 13.3-70%) and the mean
AUC 6552 (range 5999-8207). There was some correlation between rectal
symptoms and AUC but no correlation with V50.
Conclusions: From this study we can conclude that neither AUC nor V50 are
accurate predictors of acute rectal toxicity following radical radiotherapy
to the prostate, but that the AUC of the DVH shows some correlation. We
plan to monitor these patients for late sequelae to assess whether AUC is a
superior predictive factor than V50 for late rectal morbidity
P57:1
LOW DOSE CONTINUOUS HYPERFRACTIONATED
ACCELERATED RADIATION THERAPY (CHART) AS
PREOPERATIVE TREATMENT FOR RECTAL CARCINOMA
S.M Short, A. Makris, R. Glynne Jones, R. Novell, M. Harrison 
Mt Vernon Hospital, London, United Kingdom
Introduction:  To determine the feasibility of low dose CHART
as preoperative short-course treatment for locally advanced rectal
tumours.
Methods: 18 patients with locally advanced rectal carcinoma, between
1998 and 2004, entered a nonrandomised trial of preoperative low
dose CHART. Patients received 25 Gy in 15 fractions over 5 days to
a standard pelvic ﬁ  eld. Toxicity was graded using the RTOG/EORTC
acute and late toxicity scoring system. The average follow-up time is 20
months (range 0.7-52 months).
Results:  17 patients completed planned radiotherapy treatment and
went forward for surgery. One patient discontinued radiotherapy after
17 Gy and did not proceed to surgery. One patient was inoperable at the
time of surgery due to local disease extent.
Survival: Overall 4 year survival is 76% and cause speciﬁ  c survival is
87%. 2 patients died in the perioperative period due to sepsis unrelated
to tumour or radiotherapy. 2 patients died from metastatic disease, both
with primary tumour in-situ. The remainder (14) are alive without
evidence of disease
Toxicity: No patients experienced grade 3 or 4 acute toxicity. 1 patient
developed grade 2 bowel toxicity and discontinued treatment. There was
1 grade 1 bowel toxicity and 1 grade 1 wound infection after surgery.  No
patients experienced grade 2, 3 or 4 late toxicity. 5 patients experienced
grade 1 bowel toxicity and 5 late urinary symptoms.
Conclusion: Low dose CHART as preoperative short-course treatment
for rectal carcinoma is feasible with a tolerable side effect proﬁ  le. These
ﬁ  ndings compare favourably to series using 25 Gy in 5 daily fractions.
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A RETROSPECTIVE STUDY OF THE MANAGEMENT AND
OUTCOME OF PATIENTS WITH STAGE 1 (MARKER NEGATIVE) 
TERATOMA
RA Herbertson, MQ Hatton, J Coleman, RE Coleman
Weston Park Hospital, Shefﬁ  eld, United Kingdom
Purpose; To identify all patients with stage 1, marker negative teratoma
treated within a 5 year period at Weston Park Hospital in Shefﬁ  eld.  To
document patient and tumour characteristics, management at diagnosis
and relapse, method of detection of relapse and overall outcome of these
patients. 
Patients and Methods; All the relevant information was obtained from
the medical notes of the 81 patients identiﬁ  ed as having been diagnosed 
with stage 1 teratoma between 1/1/96 and 1/1/01.
Results; 43.2% of patients had a raised tumour markers pre-operatively.
46.9% of patients  had tumours which  demonstrated at least one
histological poor prognosis factor.  (46.9% had a major component
of undifferentiated structures, 40.7% demonstrated absence of yolk 
sac tumour and 18.5% had vascular invasion).  All 18.5% of patients
with vascular invasion received immediate adjuvant chemotherapy (2-3
cycles of BEP).  The remaining 64 patients were followed according to
the hospital’s surveillance program.  20% of patients relapsed.  None
of the 15 “high risk” patients who received immediate chemotherapy
relapsed.  81.3% of those who relapsed had a large component of 
undifferentiated structures compared to 30.0% in those on surveillance
who did not relapse.  The commonest method of detecting relapse was
routine CT scan.  Median time to relapse was 4.8 months.  All 16 relapsed 
patients received chemotherapy.  Complete remission was achieved for 
all patients, and overall survival was 100%.  Median disease free survival
was 45.2 months.
Discussion; The relapse rate at our centre is similar to those documented 
in the literature.  In this study, 2 cycles of adjuvant BEP in patients whose
tumour demonstrated vascular invasion seemed to prevent recurrence and 
was well tolerated.  Relapse was detected quickly (usually by CT scan)
and following chemotherapy, all patient achieved a complete remission
and remain disease free.
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QUANTITATIVE ANALYSIS OF CYCLIN DEPENDENT KINASE
INHIBITORS, P16INK4A& P21WAF1, PREDICTS NEOPLASTIC
PROGRESSION OF CERVICAL GLANDULAR  ABNORMALITIES
A El-Ghobashy, A Shaaban, J Innes, W Prime, CS Herrington 
United Kingdom, Liverpool University, Liverpool
El-Ghobashy AA, Shaaban AM, Innes J, Prime W, Herrington CS
Department of Cellular and Molecular Pathology, the University of
Liverpool, UK
Introduction: Cyclin-dependent kinase (CDK) inhibitors are
important negative regulators of cell cycle progression. Inactivation or
downregulation of the cell-cycle inhibitors, p16 and p21, are involved
in the carcinogenesis of various human tumors. Less is known about the
role of these CDK inhibitors in cervical glandular carcinogenesis.
Aim:To investigate the role of CDKs in cervical glandular neoplasia by
comparing their expression in lesions of different histological type.
Materials and Methods: Parafﬁ  n  wax-embedded sections of normal
cervix (group 1, n= 11), endometriosis/ tubo-endometrioid metaplasia
(TEM) (group 2, n= 19), cervical glandular intraepithelial neoplasia
(CGIN) (group 3, n= 33) and invasive adenocarcinoma (group 4, n=
28) were stained using monoclonal antibodies for p16INK4 and p21WAF1.
A quantitative assessment was employed for the analysis of percentage
expression of each marker. 
Results: Increase expression of  p16 occurred  from normal cervix
(median%: 0, IQ 0-1), through endometriosis/TEM (median%: 35, IQ
8-45) and CGIN (median%: 95, IQ 75-100) with no further increase
in invasive adenocarcinoma (median%: 90, IQ 80-95). The expression
of p21 in the four different groups was [0, IQ 0-0]; [0, IQ 0-3]; [1.5,
IQ 0-5] and [9, IQ 2.25-15] respectively. A cut-off value of 50% for
p16 expression and 0% for p21 expression identiﬁ  ed benign (group
1&2) from neoplastic (group 3&4) lesions with sensitivity of 90% and
speciﬁ  city of 87% for the former and 73% & 76% for the latter.
Conclusion: Our data highlight a progressive increase in p16 and p21
expression across spectrum of cervical glandular neoplasia. p16 and
p21 are useful markers to differentiate benign (groups 1 & 2) from
neoplastic (groups 2 & 3) endocervical lesions.
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DELAYS IN THE DIAGNOSIS OF COLORECTAL CANCER:
IN-DEPTH, PATIENT-CENTRED QUALITATIVE STUDY
E.M. Wood 1, R.D. Neal 2, P.L. Heywood 1, K.M. Atkin 1
1 United Kingdom, Centre for Research in Primary Care University 
of Leeds, Leeds, 2 United Kingdom, University of Wales College of 
Medicine, Cardiff
This study aims to provide a rich and detailed description of the journey
from the pre-symptomatic phase through to diagnosis, in order to identify
and explain diagnostic delays (patient, primary care and secondary care
delays)  in colorectal cancer, and to suggest strategies  for addressing
delays.
  The experience of thirty patients, newly diagnosed with colorectal cancer 
was explored t hrough  in-depth semi-structured  interviews. The related 
experiences of a family member and GP was also sought. By integrating
the perspectives of the patient, family member and GP using qualitative
analysis,  key  factors were identiﬁ  ed t hat are important  in causing
diagnostic delays.
Initial primary observations show: Most patients had heard of colorectal
cancer before their diagnosis; however the majority of patients were not
aware of symptoms speciﬁ  c to colorectal cancer, or of lifestyle/dietary
factors that may contribute to/prevent colorectal cancer. The majority
did not expect their symptoms to be due to a cancer. Patient responses to
their symptoms varied from seeking immediate medical help to a delay in
presentation. Rectal bleeding caused more concern and prompted patients
to seek medical help more quickly than with abdominal pain or change
in bowel habit. Delays occurred despite cancer concerns. Rectal bleeding
prompted immediate referral by GPs to secondary care; delays occurred 
in cases of  pain and change in bowel habit. Secondary care delays were
caused by long waiting lists for investigations and administration errors.
The results will enable us to appreciate current patient understanding
of colorectal cancer and target patient education accordingly; enable
clinicians to understand more about patient experiences and perceptions of 
these experiences; enable us to realise what issues are important, enabling
policy and practice to be sensitive to these views which in turn should  
reduce delays and improve outcomes for these patients.
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AGE AT PRESENTATION AFFECTS FREQUENCY OF B-RAF
MUTATION IN PAPILLARY THYROID CARCINOMA(PTC)
SJ Jeremiah 1, NG Powell 1, LA Stephens 1, JA Bethel 1,
TI Bogdanova 2, MD Tronko 2, GA Thomas 2
1 Human Cancer Studies Group, Swansea University, Swansea, United 
Kingdom, 2 Institute of Endocrinology and Metabolism, Kiev, Ukraine
We have investigated the frequency of B-raf mutation in a series of 31
cases of PTC in patients from Ukraine aged between 30 and 61 and 37
cases of PTC from Ukrainian patients aged under 16 at operation, 8 of
whom had been born after 1.12.86, and therefore regarded as not exposed
to radioiodine from the Chernobyl accident.  
Areas of PTC were microdissected from parafﬁ   n embedded sections,
DNA extracted and the presence of the common V600E B-raf mutation
demonstrated by PCR and restriction enzyme digestion.  PCR products
were sequenced using an ABI sequencer to conﬁ  rm the presence of the
mutation.  No mutation in B-raf was observed in any of the paired samples
of normal thyroid tissue examined; mutations were conﬁ  ned to the tumour.
18 (58%) of the adult cases harboured a B-raf V600E mutation.  Mutation
in B-raf  was more commonly associated with a classic morphology (12/
16; 75%) than a follicular variant (6/12; 50%).  The three solid variants of
PTC (normally associated with ret rearrangement) in our adult series were
negative for B-raf mutation.  The overall frequency of rearrangement is
similar to that observed in a number of other adult series. 
Only 1 of the 37  (2.7%) cases of PTC aged under 18 at operation were
positive for B-raf mutation.   The positive case was a follicular variant of
PTC and was negative for ret rearrangement.  Of the 8 PTCs from patients
born after 1.12.86, none was positive for B-raf mutation.  These results
conﬁ   rm that B-raf mutation is more commonly associated with PTC
diagnosed in adult life, and that the Ukrainian adult population shows a
similar frequency of B-raf involvement to that observed in adult series
from other countries.  
The low frequency of  B-raf involvement in juvenile PTC is therefore likely
to be associated with the age of the patient at diagnosis and morphological
subtype of  PTC, rather than a radiation aetiology.
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